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Background: Mucopolysaccharidosis type II (MPS II) is an inherited X-linked disease associated with a deficiency in
the enzyme iduronate 2-sulfatase due to iduronate 2-sulfatase gene (IDS) mutations. Recent studies in MPS II
carriers did not find clinical involvement, but these were mainly performed by anamnesis and patients’ self-reported
description of signs and symptoms. So although it is rare in heterozygous carriers, investigations in other types of
inherited X-linked disorders suggest that some clinical manifestations may be a possibility. The aim of this study
was to evaluate the clinical pattern in female carriers of MPS II and to determine whether clinical symptoms were
associated with the X-chromosome inactivation (XCI) pattern and age.
Methods: Female carriers of MPS II were genetically identified by molecular analysis of IDS. The clinical evaluation
protocol included pedigree analysis, a comprehensive anamnesis, complete physical examination, ophthalmological
evaluation, brain-evoked auditory response, electrocardiogram, echocardiogram, pulmonary function tests,
abdominal sonogram, skeletal survey, neurophysiological studies, blood cell counts and biochemistry, urine
glycosaminoglycan (GAGs) quantification, karyotype and pattern of XCI.
Results: Ten women were included in the study. The mean age of the participants was 40.2 ± 13.1 years. Six
carriers presented a skewed XCI pattern, 3 of whom (aged 38, 42 and 52 years) had increased levels of GAGs in the
urine and showed typical MPS II clinical manifestations, such as skeletal anomalies, liver abnormalities, carpal tunnel
syndrome, recurrent ear infection, hypoacusia and more frequent severe odontological problems without coarse
facial features.
Conclusions: This is the first study performing a comprehensive evaluation of heterozygous MPS II carriers. Our
results provide evidence of possible progressive, age-dependent, mild clinical manifestations in MPS II female
carriers with a skewed XCI pattern, most likely affecting the normal allele. Further comparative studies with
systematized clinical examinations in larger age-stratified populations of MPS II female carriers are required.
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Mucopolysaccharidosis type II (MPS II; OMIM 309900),
or Hunter syndrome, is one of the most common types of
X-linked recessive inherited disorder with an estimated in-
cidence between 1:110,000 and 135,500 live births [1,2]. It
is caused by a deficiency in the activity of the enzyme
iduronate 2-sulfatase (I2S; EC 3.1.6.13) that results from a
mutation in the iduronate 2-sulfatase gene (IDS). The sub-
sequent lack of glycosaminoglycan (GAGs) catabolism
leads to an accumulation of dermatan sulfate and heparan
sulfate in the lysosomes of many tissues, which makes
MPS II a multisystem disease. MPS II includes the fol-
lowing main manifestations: short stature, dysostosis
multiplex, joint contractures, coarse facies, hepatos-
plenomegaly, deafness, recurrent ear and sinopulmonary
infections, obstructive airway disease, valve abnormalities
and in several cases, mental impairment. Therefore, its
management requires a multidisciplinary approach and
specific enzyme replacement therapy, which is now avail-
able and which may change the natural history of the
disease [3].
MPS II is an X-linked recessive condition, in which fe-
male patients are infrequent. Moreover, in MPS II the X
chromosome carrying the mutant allele is expected to be
preferentially inactivated in some cells like chondrocytes
or hepatocytes. Consequently, MPS II heterozygous sub-
jects are rarely affected [4]. X-chromosome inactivation
(XCI) was investigated first by Lyon, who postulated that
only one of the X chromosomes was active in females,
with the inactivation of either the maternal or paternal
X-chromosome alleles occurring in a random and irre-
versible process [5].
Although it could be expected that females present
50:50 of active maternally and paternally derived X
chromosomes after XCI, the most common ratios are
60:40 or 70:30 [6]. Moderately skewed XCI, defined as
75:25, or severely skewed inactivation (90:10 or over),
could be pathogenic and could be associated with ad-
vanced age [7].
The presence of two alleles carrying pathological mu-
tations or a structural X-chromosome abnormality sim-
ultaneously leads to symptomatic female heterozygotes
[8]. To date, 12 case reports of females affected with
MPS II have been described in the literature; in 10 of
these cases, the disease was associated with skewed
XCI [9-18].
Recently, several clinical studies were designed to
identify any clinical manifestations in heterozygous
female carriers of MPS II. No evidence of clinical
involvement was found, despite lower plasma and
leukocyte I2S activities [8,19]. Nevertheless, these in-
vestigations were limited due to a lack of more sensitive
clinical investigations. When a systematic analysis was
undertaken in other inherited X linked diseases, suchas Fabry disease or Barth syndrome, clinical signs and
abnormal biochemical results were frequently found in
carriers [20,21].
In contrast to previous studies in which the collection
of the data was mainly performed by anamnesis and pa-
tients’ self-reported description of sign and symptoms,
the aim of this cross-sectional study was to evaluate
those clinical features using a broad panel of clinical ex-
aminations and complementary tests in ten female car-
riers of MPS II. In addition, we evaluated clinical
symptoms according to the XCI pattern and age of
participants.Methods
We included heterozygous mothers and other heterozy-
gous female relatives of MPS II male patients, previously
identified by genetic analysis, included in the Spanish
Hunter Outcome Survey (HOS) who were being seen at
participating centers. HOS is a worldwide multi-center
observational long-term follow-up registry, sponsored by
Shire HGT, which is open to all patients diagnosed with
the disease [22]. This registry was established in 2005 to
assess the natural history of Hunter syndrome and the
safety and effectiveness of enzyme replacement therapy
with idursulfase. Our study was approved by the local
Institutional Ethics Committee of the Hospital Clínico
Universitario Virgen de la Arrixaca in Murcia, Spain. In-
formed consent was obtained from all participants be-
fore beginning the study evaluation.
The clinical data were collected during carriers’ visits
to the centers by five clinicians from the Hunter Spanish
Expert Council, a group of reference in the diagnosis
and management of MPS II in Spain. Comprehensive
anamneses were obtained, including information regard-
ing the age or degree of relationship with the proband.
A systematical investigation on the extent and distribu-
tion of physical involvement in female carriers of MPS II
was conducted in 10 women using standardized clinical
examination protocols. Complete physical examination
by systems and organs was performed including full
ophthalmological evaluation, brain-evoked auditory re-
sponse, electrocardiogram, echocardiogram, pulmonary
function tests, abdominal sonogram, skeletal survey,
cognitive assessment and neurophysiological studies
(such as median nerve electrophysiological study). A
symptomatic carrier should have the characteristic signs
and symptoms classically associated to MPS II. The fol-
lowing additional analyses were also performed:
hematimetry, general biochemistry (including liver en-
zymes), quantification of GAGs in urine, karyotypes and
XCI studies.
Total GAGs were measured according to an improved
dimethylmethylene blue (DMB) test [23]. The normal
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mmol creatinine.
The cytogenetic analysis was performed on metaphase
chromosomes obtained from phytohemagglutinin (PHA)-
stimulated peripheral blood lymphocytes following stand-
ard procedures. All chromosome preparations were
G-banded and analyzed with a minimum resolution
of 550 to 600 bands [24].
The X-inactivation pattern was determined from per-
ipheral lymphocytes by polymerase chain reaction (PCR)
analysis of a polymorphic CAG trinucleotide repeat in
the polyglutamine region of the androgen receptor (AR)
gene [25]. The XCI pattern was defined as skewed with
a cut-off value of ≥75:25 of the X-inactivation ratio
(moderately skewed inactivation) and ≥90:10 (severely
skewed), and the 50:50 cut-off value was defined as ran-
dom [7,26].
Results
Ten female carriers of MPS II from 6 unrelated families
with no parental consanguinity participated in the study.
The mean age of the participants was 40.5 ± 13.1 and
ranged from 17 to 67 years. The majority of the partici-
pating women were mothers (n = 6) of previously diag-
nosed MPS II patients recruited in the HOS registry, but
there was also one grandmother, one aunt, one sister
and one cousin.
The carriers’ information at baseline, including med-
ical history and/or physical examination, is presented in
Additional file 1: Table S1 and is split into two groups
according to the patients’ age (≥40 or <40). Globally,
missense point mutations in IDS were seen in five fam-
ilies and a small deletion in one. Only two of the mis-
sense mutations were previously described (c.998C>T
and c.1048A>C). The karyotypes were normal in all
women (data not shown). Extreme skewing XCI pattern
was not identified in any of them. Moderately skewed
XCI pattern was found in 6 women, of whom 4 were
40 years or older. Three out of six had increased GAGs.
Therefore, a conjunction of skewed XCI pattern and
GAGs elevation was observed in 2 / 5 aged carriers
(≥ 40 years) and 1 / 5 in the group (< 40 years).
The results of the clinical examinations and comple-
mentary examinations are also described in Additional file
1: Table S1. None of them showed coarse facial features.
Six female carriers presented overweight or obesity. Three
carriers, aged 38, 42 and 52, showed moderately skewed
XCI pattern (75:25, 81:19 and 86:14 respectively), in-
creased GAGs levels and clinically significant Hunter dis-
ease manifestations, especially in the older ones. For
example, female number 1 (52 years old) presented den-
tures since her twenties, recurrent acute otitis, eardrum
perforation, bilateral neurosensorial deafness, broncho-
pathy, hepatomegaly, neurological and skeletal findings,and mild to moderate carpal tunnel syndrome (CTS). Skel-
etal anomalies, short stature and CTS were predominant
symptoms in female carrier number 2 (42 year). Female
number 6 (38 years) showed important odontological
problems, recurrent otitis media, bilateral neurosensorial
hypoacusia and mild skeletal manifestations with preco-
cious degenerative spine changes.
Overall, the laboratory data revealed that platelets were
increased up to 4.83 × 105 in 5 / 9 carriers (Data not
shown). The neurophysiological examination detected 3 / 5
women with mild to moderate CTS. The cognitive assess-
ment identified 5 / 7 females with normal intelligence quo-
tient (IQ) scores, one with a low IQ and the oldest female
carrier with Hunter manifestations who presented a lim-
ited borderline score, according to the Kaufman Brief
Intelligence test and the Wechsler Intelligence Scale for
Adults. These two females were from the same family.
Echographics and imaging exams were not performed
in all women for technical reasons. Abdominal imaging
was obtained from 6 participants, with hepatic anomalies
observed in 3 who also showed other Hunter manifesta-
tions (1 mild hepatomegaly, 2 mild hepatic steatosis). All
3 carriers with increased GAG levels presented degen-
erative bone changes. The 42-year old carrier (number
2) showed hip dysplasia and typical Hunter paddle-
shaped ribs (Figure 1 X-ray image). Except for a minimal
aortic insufficiency with dilatation in the oldest partici-
pant with increased levels of GAGs (number 1), none of
the rest of the participants presented abnormalities in
echocardiogram or electrocardiogram. Brain MRI was per-
formed in eight carriers and was normal in all of them.
Discussion
As many X-linked diseases, in MPS II has been assumed
that female carriers remain asymptomatic. Moreover, re-
cent publications have found no evidence for clinical in-
volvement in heterozygous female carriers, although
there was a slightly lower IDS activity in plasma and leu-
kocytes compared to non-heterozygotes [8,19]. Never-
theless, in carriers of other recessive inherited X-linked
disorders, such as Fabry disease [20] or Barth syndrome
[21], systematic explorations showed some clinical mani-
festations, which were not previously described. In con-
trast to previous studies, our results show that the
presence of clinical manifestations might be not uncom-
mon in MPS II female heterozygous when a comprehen-
sive evaluation is performed. Moreover, some of these
women may exhibit typical clinical features of the dis-
ease. The most frequent symptomatology found in this
study has been precocious odontological problems, bone
anomalies, respiratory and ear problems, CTS and hep-
atic anomalies.
In MPS II, over 300 types of mutations in the IDS gene
have been identified [27], most of them are private and
Figure 1 Paddle-shaped ribs with narrowing at the
vertebral end.
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was observed in 5 / 6 families and a novel mutation in
4 / 6 families. There may be a correlation between geno-
type / phenotype, so that severity of the mutation could
have an impact in the way the disease is clinically
manifested. For example, the mutation in carrier 6 is se-
vere as it leads to a protein frameshift and may be asso-
ciated with an earlier symptomatology.
Together with the I2S enzyme activity and IDS muta-
tion test, GAGs quantification in urine is the gold stand-
ard for the diagnosis of MPS II. We used the method
described by Stone et al., which is widely used in the lit-
erature [23]. Three of 10 participants showed elevated
GAGs levels in urine.
First described by Lyon [5], XCI or lyonization appears
to be involved in many X-linked transmitting processes
in female carriers, such as MPS II. The variability in X
inactivation produces milder clinical phenotypes in fe-
males, often more variable than in males [5,28,29]. Al-
though for some authors skewed XCI was essential in
the phenotype expression in heterozygotes of X-linked
diseases and particularly in Fabry disease [30-32], others
did not find a correlation with phenotype or severity,
concluding that XCI in leukocytes of females with Fabry
disease was not useful for predicting prognosis and
should not be used to define therapeutic options [33]. Ina normal situation, a random X inactivation of the same
allele in 50% of cells (50:50) or 60:40 is expected [6],
but a skewing pattern, defined as a inactivation ≥ 75:25,
may lead to X-linked pathologies even in women [20]. In
our results, 6 / 10 female carriers of MPS II showed
skewed XCI pattern. This pattern was also described in
previously published clinical case reports in females
[9-18] and represents a higher rate than expected for
healthy female population. As per Salsano et al. investi-
gation on X-linked adrenoleukodystrophy, moderately
skewed XCI was found in 22.4% of healthy subjects in
the control group [26] and Sharp et al. obtained a rate of
16% in normal women over 60 years old [34]. Some
other investigations additionally described that symp-
tomatic heterozygotes usually present skewed X inactiva-
tion with a predominant expression of the mutated allele
[35]. This was a limitation in our study, as we did not
determine the allele that was preferentially inactivated,
similarly to the de Camargo investigation [19]. Although
no significant correlation has been found between the
levels of leukocyte IDS activity and the levels of urinary
GAGs in MPS II carriers [8], the occurrence of clinical
manifestations in some of our carriers presented both
skewed inactivation and elevated GAGs suggesting that
the mutated allele might be preferentially expressed [8].
The most frequent and significant clinical anomalies
were bone changes and mild to moderate CTS and
neurosensorial hypoacusia, identified by specific comple-
mentary examinations (skeletal survey, median nerve
electrophysiological study and brain-evoked auditory re-
sponse), not by patient-reported anamnesis.
Subjects were divided according to their age, in order
to evaluate whether symptomatology was stronger at
older ages, because it is known that the proportion of fe-
males showing a highly skewed pattern of X inactivation
increases markedly with age. Life expectancy has been
recently established in around 80 years old (84,57 years
old) [36], therefore we select the age of 40 years old to
divide subjects into groups and ensure we gather both
first and last vital periods of women.
XCI increases in tissues with age, reaching up to 40%
of skewed lyonization in women aged 60 or over [6].
The skewing process does not seem to reflect a single
heritable genetic locus, but rather corresponds to a
complex trait determined by the combinatorial effect of
stochastic events and selection biases occurring after
primary XCI, caused by X-linked allelic variants of
genes affecting cellular growth [37]. The age-skewing
process has been described in several investigations, but
the clinical significance of this finding is still uncertain
[26,37-39]. According to our results, the mean age of
the patients was 40.5 ± 13.1 years, which was slightly
older compared with other investigations (Schwartz
et al.: 35.5 ± 8.6 years [8]; de Camargo et al.: 36.1 ±
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showed moderately skewed inactivation, 2 of which had
a greater symptomatology in conjunction with elevated
GAG levels. In heterozygotes for X-linked disorders, the
degree of skewing is expected to be correlated with
the degree to which females present symptoms of the
X-linked disease [8]. As explained before, in some
X-linked disorders, such as Fabry disease, a consistent
relationship between phenotype and XCI in blood cells
could not be confirmed and it was hypothesized that
other cell tissues should be more appropriate for the
analysis [33]. In our results, the severity of the symp-
toms is greater in the oldest carrier with higher skewing
XCI pattern female carrier 1 with 52 years (86:14),
followed by female 2 with 42 years (81:19) and female 3
with 38 years (75:25). Interestingly, female carrier 1 had
a normal abdominal ultrasound 4 years before which
also might suggest the progression of the symptoms
with age.
Unfortunately, I2S enzyme activity was not measured in
these women. It is already known that MPS II carriers
show lower plasma and leukocyte I2S activities when com-
pared with no carriers but this reduction was not associ-
ated, in Schwartz study, either with increased levels of
urinary GAGs or with the occurrence of clinical manifes-
tations [8]. Furthermore, they pointed out that I2S activity
measured in other cell types, such as chondrocytes or he-
patocytes, should be more relevant to evaluate the pro-
gression of the disease.
Pinto et al. explained that the major differences in
clinical manifestations among X-linked diseases may de-
pend on the cell autonomy of the gene product involved
and, therefore, on the occurrence of cross-correction
mechanism, which was deficient in Fabry disease and
preserved in MPS II [4]. It was suggested that MPS
symptomatic heterozygotes would present skewed X-
inactivation with predominant expression of the mutant
allele [4].
Previous investigations on MPS II were based on data
from medical history and patients’ anamnesis about signs
and symptoms in organs and systems typically involved in
MPS II [8,19]. In the work of de Camargo et al., the anam-
nesis was focused on cardiologic, pulmonary, bone, and
gastric problems, while the complementary exams in-
cluded brain magnetic resonance imaging, liver, spleen,
and spine computed tomography scans [19]. Additionally,
they determined plasma and leukocyte IDS activity,
urinary levels of GAGs, karyotyping and conducted an
X-inactivation assay [19]. Also, Schwartz et al. collected
the medical history and performed the physical examin-
ation according to expected MPS II symptomatology; and
included a leukocyte IDS activity and GAGs determination
in 24-hour urine samples [8]. Therefore, little data is avail-
able on cognitive and neurophysiological alterations,which may not be sufficient to identify a subtle clinical
symptomatology. This is the first study performing a com-
prehensive evaluation of heterozygous MPS II carriers, in
where a complete physical examination was conducted in-
dividually by system and organ, including a full ophthal-
mological evaluation, brain-evoked auditory response,
electrocardiogram, echocardiogram, pulmonary function
tests, abdominal sonogram, skeletal survey, cognitive as-
sessment and neurophysiological studies (such as median
nerve electrophysiological study).
We found certain clinical signs in the whole group of
carriers, such as CTS diagnosed in 4 / 6 women and
mild hepatic pathologies described in 3 / 6 participants.
Additionally, moderate to severe periodontal disease or
dental abscess in 6 / 9 participants and an elevation of
platelets was observed in 5 / 9 participants. We are not
aware of previous reports of platelet alterations associ-
ated with this type of mucopolysaccharidosis and cer-
tainly we cannot describe the practical significance of
this finding.
Overall, we found 3 carriers aged 38, 42 and 52 show-
ing some typical MPS II clinical manifestations, includ-
ing recurrent acute otitis, bilateral neurosensorial
deafness, dentature since their twenties, hepatomegaly,
skeletal anomalies and mild to moderate CTS, skewed
XCI and GAGs elevation. Subjects aged 42 and 52 years
(number 1 and 2, respectively) are sisters and signs and
symptoms of the disease were more clearly evident in
the older women, so it is possible that MPS II’s pene-
trance and clinical severity index in female carriers in-
crease with age.
It would have been interesting to study also non-
heterozygotes females as part of a control group, be-
cause some of these clinical findings may be commonly
found in healthy population. Nevertheless, the work was
conducted inside the public health care system and we
were limited given the costly and comprehensive work-
up to be done in females without added risk factors
(such as MPS II carriers). The small population of our
study makes it difficult to reach a conclusive result, but
our data provide traces of subtle clinical and biochemical
signs in female carriers of MPS II.
Conclusions
These results suggest that, like other X-linked diseases,
MPS II heterozygotes may show a progressive disease
phenotype, and this appears to be associated with a sig-
nificant skewing of X-inactivation, presumably in the
normal allele. The evolution of signs and symptoms is
often a better indicator of MPS II involvement than a
static snapshot of the presence or absence of certain
manifestations. Therefore, it is important to monitor
changes over time. It would be convenient that MPS
heterozygotes are monitored closely at least every 12–
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sessments should include evaluation of the musculoskel-
etal and cardiovascular systems, ears, airways, eyes, skin,
nervous system, abdomen and gastrointestinal system, as
outlined in Additional file 1: Table S1. More frequent as-
sessment might be necessary in those in whom signs
and symptoms are progressing and eventually the avail-
able treatment options should be discussed in symptom-
atic heterozygous females.
However, further comprehensive studies that look for
subtle signs and symptoms of this disease are required
in a larger age-stratified female carrier population.
Additional file
Additional file 1: Table S1. Clinical, biochemical and genetic data in
MPS II female carriers.
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